Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study.

Helen TesfayeKatherine M WangLuke E ZabotkaDeborah J WexlerNiklas SchmedtLisette KoenemanLeo SemanJulie M PaikElisabetta Patorno

Published in: Journal of general internal medicine (2024)

Among adults with T2D, the initiation of empagliflozin vs a DPP4i or GLP-1RA was associated with lower risk of incident gout, complementing results from a post hoc analysis of the EMPA-REG OUTCOME trial and previously published observational research focusing on the sodium-glucose co-transporter-2 inhibitor class in more narrowly defined study populations.

Keyphrases

cardiovascular disease
uric acid
rheumatoid arthritis
clinical trial
study protocol
randomized controlled trial
phase iii
type diabetes
systematic review
metabolic syndrome
cross sectional
disease activity
systemic sclerosis
meta analyses